SCHEMBL3792203

SCHEMBL3792203

O=C1Nc2ccccc2/C1=C/c1ccc2c(-c3ccn[nH]3)n[nH]c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLK2 Q86UE8 1/20 0.53
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
MAPT P10636 4/20 0.46
MAPK1 P28482 3/20 0.46
PLK4 O00444 2/20 0.46
PLK1 P53350 2/20 0.46
HTT P42858 1/20 0.46
PDGFRB P09619 4/20 0.46
RET P07949 1/20 0.46
FLT3 P36888 1/20 0.46
KDR P35968 1/20 0.46
APP P05067 3/20 0.44
SNCA P37840 3/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792204 1.00 TLK2 (0.53) TLK2PSEN1PSEN2APH1BNCSTN
SCHEMBL12848217 1.00 TLK2 (0.53) TLK2PSEN1PSEN2APH1BNCSTN
SCHEMBL3791719 0.85 PDGFRB (0.49) TLK2PSEN1PSEN2APH1BNCSTN
SCHEMBL3791715 0.85 PDGFRB (0.49) TLK2PSEN1PSEN2APH1BNCSTN
SCHEMBL12848485 0.85 PDGFRB (0.49) TLK2PSEN1PSEN2APH1BNCSTN
SCHEMBL12795294 0.85 MAPT (0.51) TLK2PSEN1PSEN2APH1BNCSTN
SCHEMBL3713707 0.84 ITK (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3713709 0.84 ITK (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6531295 0.84 ITK (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3707160 0.82 TTK (0.60) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
EP-2235004-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER University Health Network (CA) 2010-10-06 EP disclosed
WO-2009079767-A9 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-10-01 WO disclosed
WO-2009079767-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 TLK2 202/4885PSEN1 3988/4885PSEN2 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.